Found: 16
Select item for more details and to access through your institution.
Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden.
- Published in:
- Pharmacology Research & Perspectives, 2020, v. 8, n. 6, p. 1, doi. 10.1002/prp2.685
- By:
- Publication type:
- Article
Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 485, doi. 10.1159/000515817
- By:
- Publication type:
- Article
Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 485, doi. 10.1159/000515817
- By:
- Publication type:
- Article
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 8, p. 3635, doi. 10.1007/s12325-022-02170-w
- By:
- Publication type:
- Article
Incidence and risk of intestinal and extra-intestinal complications in Medicaid patients with inflammatory bowel disease: a 5-year population-based study.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 11, p. 1393, doi. 10.1002/jcph.2074
- By:
- Publication type:
- Article
Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 7, p. 905, doi. 10.1002/jcph.2021
- By:
- Publication type:
- Article
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 6, p. 1, doi. 10.1111/cts.13825
- By:
- Publication type:
- Article
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
- Published in:
- British Journal of Clinical Pharmacology, 2017, v. 83, n. 12, p. 2767, doi. 10.1111/bcp.13381
- By:
- Publication type:
- Article
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 114, n. 3, p. 644, doi. 10.1002/cpt.2953
- By:
- Publication type:
- Article
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 10, p. 1171, doi. 10.1002/psp4.12686
- By:
- Publication type:
- Article
Population repeated time‐to‐event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 10, p. 1221, doi. 10.1002/psp4.12690
- By:
- Publication type:
- Article
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC‐0214 in healthy volunteers.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 5, p. 1225, doi. 10.1111/cts.13240
- By:
- Publication type:
- Article
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1).
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 1, p. 130, doi. 10.1111/cts.13127
- By:
- Publication type:
- Article